Innova Captab
NSE: INNOVACAP · ISIN INE0DUT01020 · Healthcare
₹1,060.20−7.10 (−0.67%)
Monday 9 November, 12:18 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,060.20 −7.10 (−0.67%) today
The day
- Previous close
- ₹1,067.30
- Open
- ₹1,069.00
- Day high
- ₹1,087.80
- Day low
- ₹1,050.20
Listed on NSE since 29 December 2023.
Key numbers
- Market value
- ₹5,843.24 Cr
- P/E (trailing)
- 37.95
- EPS (trailing)
- ₹26.91
- Price to book
- 5.36
- Dividend yield
- 0.39%
- Debt to equity
- 0.32
- Profit margin
- 8.8%
- Beta
- 0.13
- Volume today
- 49,468
- Average volume
- 1.04 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹925.40 Cr | ₹67.95 Cr |
| FY24 | ₹1,076.96 Cr | ₹94.35 Cr |
| FY25 | ₹1,234.42 Cr | ₹128.26 Cr |
| FY26 | ₹1,603.91 Cr | ₹140.92 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹471 Cr | ₹0 | −100.0% |
| Q4 FY26Jan–Mar 2026Audited | ₹448 Cr | ₹0 | – |
| Q3 FY26Oct–Dec 2025 | ₹450 Cr | ₹0 | – |
| Q2 FY26Jul–Sep 2025 | ₹380 Cr | ₹30 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹352 Cr | ₹31 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹315 Cr | ₹0 | – |
Source: Innova Captab’s results filed with NSE, consolidated (the whole group). Net profit is the share of Innova Captab’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹839 Cr | ₹837 Cr |
| Investments | ₹41 Cr | ₹0 |
| Inventories | ₹283 Cr | ₹236 Cr |
| Owed by customers | ₹437 Cr | ₹395 Cr |
| Cash and equivalents | ₹3 Cr | ₹53.90 L |
| Total assets | ₹1,838 Cr | ₹1,692 Cr |
| Borrowings | ₹344 Cr | ₹336 Cr |
| Total liabilities | ₹756 Cr | ₹671 Cr |
| Shareholders’ equity | ₹1,082 Cr | ₹1,021 Cr |
Source: Innova Captab’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Innova Captab
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Panchkula
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Innova Captab in the last day or two.
Dividends and corporate actions
All companies- Interim Dividend - Rs 2 Per Share
Dividend · ex-date 30 January 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.